Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 9/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335428 | 0.87 | P2RX7 (0.39) | CYP3A4P2RX7CYP2C9ALDH1A1TSHR | |
| SCHEMBL6335486 | 0.82 | EED (0.43) | CYP3A4P2RX7PGRCYP2C9ALDH1A1 | |
| SCHEMBL6326125 | 0.82 | ALDH1A1 (0.41) | P2RX7ALDH1A1CYP2D6 | |
| SCHEMBL6328756 | 0.82 | P2RX7 (0.36) | CYP3A4P2RX7CYP2C9TSHRCYP2D6 | |
| SCHEMBL6335791 | 0.82 | PNMT (0.37) | DPP4CYP3A4P2RX7CYP2C9TSHR | |
| SCHEMBL6326732 | 0.81 | P2RX7 (0.34) | CYP3A4P2RX7CYP2C9TSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL6326208 | 0.81 | PNMT (0.36) | DPP4CYP3A4P2RX7CYP2C9TSHR | |
| SCHEMBL6330593 | 0.80 | CYP2D6 (0.43) | CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6326202 | 0.79 | CYP2C9 (0.43) | CYP2C9ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6329192 | 0.77 | CYP2D6 (0.34) | CYP3A4P2RX7CYP2C9TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | DPP4 3550/4885CYP3A4 4535/4885P2RX7 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.